Apicidin potentiates the imatinib-induced apoptosis of Bcr-Abl-positive human leukaemia cells by enhancing the activation of mitochondria-dependent caspase cascades

British Journal of Haematology

Volumn 124, Issue 2, 2004, Pages 166-178

  Kim, Jin Seok ^a   Jeung, Hoi Kyung ^b   Cheong, June Won ^b   Maeng, Hoyoung ^b   Lee, Seung Tae ^b   Hahn, Jee Sook ^b   Ko, Yun Woong ^b   Min, Yoo Hong ^b  

^a National Health Insurance Corporation   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

Author keywords

Apicidin; Bcr Abl; Histone deacetylase inhibitor; Imatinib; Leukaemia

Indexed keywords

APICIDIN; BCR ABL PROTEIN; BINDING PROTEIN; CASPASE; IMATINIB; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE; X LINKED INHIBITOR OF APOPTOSIS;

APOPTOSIS; ARTICLE; BLAST CELL; CELL DAMAGE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOSOL; DISEASE COURSE; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; HUMAN; HUMAN CELL; LEUKEMIA CELL; MITOCHONDRIAL RESPIRATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; REACTOR CASCADE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BLOTTING, WESTERN; CASPASES; DRUG SYNERGISM; ENZYME INHIBITORS; GENES, ABL; HISTONE DEACETYLASES; HUMANS; K562 CELLS; LEUKEMIA, MYELOID, CHRONIC; MITOCHONDRIA; PEPTIDES, CYCLIC; PIPERAZINES; PYRIMIDINES;

EID: 1642580501     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2003.04759.x     Document Type: Article

References (55)

1. Adrain, C., Creagh, E.M. & Martin, S.J. (2001) Apoptosis-associated release of Smac/DIABLO from mitochondria requires active caspases and is blocked by Bcl-2. European Molecular Biology Organization Journal, 20, 6627-6636.
2. Amarante-Mendes, G.P., Kim, C.N., Liu, L., Huang, Y., Perkins, C.L., Green, D.R. & Bhalla, K. (1998a) Bcr-Abl exerts its antiapoptotic effect against diverse apoptotic stimuli through blockage of mitochondrial release of cytochrome c and activation of caspase-3. Blood, 91, 1700-1705.
3. Amarante-Mendes, G.P., McGahon, A.J., Nishioka, W.K., Afar, D.E., Witte, O.N. & Green, D.R. (1998b) Bcl-2-independent Bcr-Abl-mediated resistance to apoptosis: protection is correlated with up regulation of Bcl-xL. Oncogene, 16, 1383-1390.
4. Bedi, A., Barber, J.P., Bedi, G.C., el-Deiry, W.S., Sidransky, D., Vala, M.S., Akhtar, A.J., Hilton, J. & Jones, R.J. (1995) BCR-ABL-mediated inhibition of apoptosis with delay of G2/M transition after DNA damage: a mechanism of resistance to multiple anticancer agents. Blood, 86, 1148-1158.
5. Ben-Neriah, Y., Daley, G.Q., Mes-Masson, A.M., Witte, O.N. & Baltimore, D. (1986) The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene. Science, 233, 212-214.
6. Bernhard, D., Skvortsov, S., Tinhofer, I., Hubl, H., Greil, R., Csordas, A. & Kofler, R. (2001) Inhibition of histone deacetylase activity enhances Fas receptor-mediated apoptosis in leukemia lymphoblasts. Cell Death and Differentiation, 9, 1014-1021.
7. Bossy-Wetzel, E. & Green, D.R. (1999) Caspases induce cytochrome c release from mitochondria by activating cytosolic factors. Journal of Biological Chemistry, 274, 17484-17490.
8. Cheong, J.W., Chong, S.Y., Kim, J.Y., Eom, J.I., Jeung, H.K., Maeng, H.Y., Lee, S.T. & Min, Y.H. Induction of apoptosis by apicidin, a histone deacetylase inhibitor, via the activation of mitochondria-dependent caspase cascade in human Bcr-Abl-positive leukemia cells.. Clinical Cancer Research, 4, 5018-5027.
9. Cress, W.D. & Seto, E. (2000) Histone deacetylases, transcriptional control, and cancer. Journal of Cellular Physiology, 184, 1-16.
10. Dan, S., Naito, M. & Tsuruo, T. (1998) Selective induction of apoptosis in Philadelphia chromosome-positive chronic myelogenous leukemia cells by an inhibitor of BCR-ABL tyrosine kinase, CGP 57148. Cell Death and Differentiation, 5, 710-715.
11. Deininger, M.W., Goldman, J.M., Lydon, N. & Melo, J.V. (1997) The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood, 90, 3691-3698.
12. Deveraux, Q.L., Takahashi, R., Salvesen, G.S. & Reed, J.C. (1997) X-linked IAP is a direct inhibitor of cell-death proteases. Nature, 388, 300-304.
13. Deveraux, Q.L., Roy, N., Stennicke, H.R., Van Arsdale, T., Zhou, Q., Srinivasula, S.M., Alnemri, E.S., Salvesen, G.S. & Reed, J.C. (1998) IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases. European Molecular Biology Organization Journal, 17, 2215-2223.
14. Deveraux, Q.L., Leo, E., Stennicke, H.R., Welsh, K., Salvesen, G.S. & Reed, J.C. (1999) Cleavage of human inhibitor of apoptosis protein XIAP results in fragments with distinct specificities for caspases. European Molecular Biology Organization Journal, 18, 5242-5251.
15. Druker, B.J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G.M., Fanning, S., Zimmermann, J. & Lydon, N.B. (1996) Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nature Medicine, 2, 561-566.
16. Druker, B.J., Talpaz, M., Resta, D.J., Peng, B., Buchdunger, E., Ford, J.M., Lydon, N.B., Kantarjian, H., Capdeville, R., Ohno-Jones, S. & Sawyers, C.L. (2001a) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. New England Journal of Medicine, 344, 1031-1037.
17. Druker, B.J., Sawyers, C.L., Kantarjian, H., Resta, D.J., Reese, S.F., Ford, J.M., Capdeville, R. & Talpaz, M. (2001b) Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. New England Journal of Medicine, 344, 1038-1042.
18. Du, C., Fang, M., Li, Y., Li, L. & Wang, X. (2000) Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell, 102, 33-42.
19. Fang, G., Kim, C.N., Perkins, C.L., Ramadevi, N., Winton, E., Wittmann, S. & Bhalla, K.N. (2000) CGP57148B (STI-571) induces differentiation and apoptosis and sensitizes Bcr-Abl-positive human leukemia cells to apoptosis due to antileukemic drugs. Blood, 96, 2246-2253.
20. Gambacorti-Passerini, C., Barni, R., le Coutre, P., Zucchetti, M., Cabrita, G., Cleris, L., Rossi, F., Gianazza, E., Brueggen, J., Cozens, R., Pioltelli, P., Pogliani, E., Corneo, G., Formelli, F. & D'Incalci, M. (2000) Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571. Journal of the National Cancer Institute, 92, 1641-1650.
21. Gorre, M.E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P.N. & Sawyers, C.L. (2001) Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science, 293, 876-880.
22. Han, J.W., Ahn, S.H., Park, S.H., Wang, S.Y., Bae, G.U., Seo, D.W., Kwon, H.K., Hong, S., Lee, H.Y., Lee, Y.W. & Lee, H.W. (2000) Apicidin, a histone deacetylase inhibitor, inhibits proliferation of tumor cells via induction of p21WAF1/Cip1 and gelsolin. Cancer Research, 60, 6068-6074.
23. Hochhaus, A., Kreil, S., Corbin, A., La Rosee, P., Lahaye, T., Berger, U., Cross, N.C., Linkesch, W., Druker, B.J., Hehlmann, R., Gambacorti-Passerini, C., Corneo, G. & D'Incalci, M. (2001) Roots of clinical resistance to STI-571 cancer therapy. Science, 293, 2163.
24. Holyoake, D.T. (2001) Recent advances in the molecular and cellular biology of chronic myeloid leukaemia: lessons to be learned from the laboratory. British Journal of Haematology, 113, 11-23.
25. Kano, Y., Akutsu, M., Tsunoda, S., Mano, H., Sato, Y., Honma, Y. & Furukawa, Y. (2001) In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents. Blood, 97, 1999-2007.
26. Khochbin, S., Verdel, A., Lemercier, C. & Seigneurin-Berny, D. (2001) Functional significance of histone deacetylase diversity. Current Opinion in Genetics and Development, 11, 162-166.
27. Klejman, A., Rushen, L., Morrione, A., Slupianek, A. & Skorski, T. (2002) Phosphatidylinositol-3 kinase inhibitors enhance the antileukemia effect of STI571. Oncogene, 21, 5868-5876.
28. Kouzarides, T. (1999) Histone acetylases and deacetylases in cell proliferation. Current Opinion in Genetics and Development, 9, 40-48.
29. Kwon, S.H., Ahn, S.H., Kim, Y.K., Bae, G.U., Yoon, J.W., Hong, S., Lee, H.Y., Lee, Y.W., Lee, H.W. & Han, J.W. (2002) Apicidin, a histone deacetylase inhibitor, induces apoptosis and Fas/Fas ligand expression in human acute promyelocytic leukemia cells. Journal of Biological Chemistry, 277, 2073-2080.
30. Lugo, T.G., Pendergast, A.M., Muller, A.J. & Witte, O.N. (1990) Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science, 247, 1079-1082.
31. McGahon, A., Bissonnette, R., Schmitt, M., Cotter, K.M., Green, D.R. & Cotter, T.G. (1994) BCR-ABL maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death. Blood, 83, 1179-1187.
32. Marks, P.A., Richon, V.M. & Pifkind, R.A. (2000) Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. Journal of the National Cancer Institute, 92, 1210-1216.
33. Marzo, I., Brenner, C., Zamzami, N., Susin, S.A., Beutner, G., Brdiczka, D., Remy, R., Xie, Z.H., Reed, J.C. & Kroemer, G. (1998) The permeability transition pore complex: a target for apoptosis regulation by caspases and bcl-2-related proteins. Journal of Experimental Medicine, 187, 1261-1271.
34. Nimmanapalli, R., Porosnicu, M., Nguyen, D., Worthington, E., O'Bryan, E., Perkins, C. & Bhalla, K. (2001a) Cotreatment with STI-571 enhances tumor necrosis factor alpha-related apoptosis-inducing ligand (TRAIL or apo-2L)-induced apoptosis of Bcr-Abl-positive human acute leukemia cells. Clinical Cancer Research, 7, 350-357.
35. Nimmanapalli, R., O'Bryan, E. & Bhalla, K. (2001b) Geldanamycin and its analogue 17-allylamino-17-demethoxygeldanamycin lowers Bcr-Abl levels and induces apoptosis and differentiation of Bcr-Abl-positive human leukemic blasts. Cancer Research, 61, 1799-1804.
36. Nimmanapalli, R., Fuino, L., Stobaugh, C., Richon, V. & Bhalla, K. (2003) Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells. Blood, 101, 3236-3239.
37. Pazin, M.J. & Kadonaga, J.T. (1997) What's up and down with histone deacetylation and transcription? Cell, 89, 325-328.
38. Porosnicu, M., Nimmanapalli, R., Nguyen, D., Worthington, E., Perkins, C. & Bhalla, K.N. (2001) Co-treatment with As2O3 enhances selective cytotoxic effects of STI-571 against Brc-Abl-positive acute leukemia cells. Leukemia, 15, 772-778.
39. Ray, S., Bullock, G., Nunez, G., Tang, C., Ibrado, A.M., Huang, Y. & Bhalla, K. (1996) Enforced expression of Bcl-XS induces differentiation and sensitizes chronic myelogenous leukemia-blast crisis K562 cells to 1-beta-D-arabinofuranosylcytosine-mediated differentiation and apoptosis. Cell Growth and Differentiation, 7, 1617-1623.
40. Reuther, J.Y., Reuther, G.W., Cortez, D., Pendergast, A.M. & Baldwin, A.S. Jr (1998) A requirement for NF-κ B activation in Bcr-Abl-mediated transformation. Genes and Development, 12, 968-981.
41. Sawyers, C.L., Hochhaus, A., Feldman, E., Goldman, J.M., Miller, C.B., Ottmann, O.G., Schiffer, C.A., Talpaz, M., Guilhot, F., Deininger, M.W., Fischer, T., O'Brien, S.G., Stone, R.M., Gambacorti-Passerini, C.B., Russell, N.H., Reiffers, J.J., Shea, T.C., Chapuis, B., Coutre, S., Tura, S., Morra, E., Larson, R.A., Saven, A., Peschel, C., Gratwohl, A., Mandelli, F., Ben-Am, M., Gathmann, I., Capdeville, R., Paquette, R.L. & Druker, B.J. (2002) Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood, 99, 3530-3539.
42. Skorski, T., Bellacosa, A., Nieborowska-Skorska, M., Majewski, M., Martinez, R., Choi, J.K., Trotta, R., Wlodarski, P., Perrotti, D., Chan, T.O., Wasik, M.A., Tsichlis, P.N. & Calabretta, B. (1997) Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway. European Molecular Biology Organization Journal, 16, 6151-6161.
43. Slee, E.A., Harte, M.T, Kluck, R.M., Wolf, B.B., Casiano, C.A., Newmeyer, D.D., Wang, H.G., Reed, J.C., Nicholson, D.W., Alnemri, E.S., Green, D.R. & Martin, S.J. (1999) Ordering the cytochrome c-initiated caspase cascade: hierarchical activation of caspases-2, -3, -6, -7, -8, and -10 in a caspase-9-dependent manner. Journal of Cell Biology, 144, 281-292.
44. Steinman, R.A. & Johnson, D.E. (2000) p21WAF1 prevents down-modulation of the apoptotic inhibitor protein c-IAP1 and inhibits leukemic apoptosis. Molecular Medicine, 6, 736-749.
45. Struhl, K. (1998) Histone acetylation and transcriptional regulatory mechanisms. Genes and Development, 12, 599-606.
46. Tang, D., Lahti, J.M. & Kidd, V.J. (2000) Caspase-8 activation and bid cleavage contribute to MCF7 cellular execution in a caspase-3-dependent manner during staurosporin-mediated apoptosis. Journal of Biological Chemistry, 275, 9303-9307.
47. Thiesing, J.T., Ohno-Jones, S., Kolibaba, K.S. & Druker, B.J. (2000) Efficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-abl-positive cells. Blood, 96, 3195-3199.
48. Topaly, J., Zeller, W.J. & Fruehauf, S. (2001) Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells. Leukemia, 15, 342-347.
49. Verhagen, A.M., Ekert, P.G., Pakusch, M., Silke, J., Connolly, L.M., Reid, G.E., Moritz, R.L., Simpson, R.J. & Vaux, D.L. (2000) Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell, 102, 43-53.
50. Vigushin, D.M. & Coombes, R.C. (2002) Histone deacetylase inhibitors in cancer treatment. Anticancer Drugs, 13, 1-13.
51. Vrana, J.A., Decker, R.H., Johnson, C.R., Wang, Z., Jarvis, W.D., Richon, V.M., Ehinger, M., Fisher, P.B. & Grant, S. (1999) Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-XL, c-Jun, and p21CIP1, but independent of p53. Oncogene, 18, 7016-7025.
52. Wolffe, A.P. (1997) Transcriptional control. Sinful repression. Nature, 387, 16-17.
53. Yang, Y., Fang, S., Jensen, J.P., Weissman, A.M. & Ashwell, J.D. (2000) Ubiquitin protein ligase activity of IAPs and their degradation in proteasomes in response to apoptotic stimuli. Science, 288, 874-877.
54. Yu, C., Krystal, G., Varticovksi, L., McKinstry, R., Rahmani, M., Dent, P. & Grant, S. (2002a) Pharmacologic mitogen-activated protein/ extracellular signal-regulated kinase kinase/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr/Abl-expressing human leukemia cells. Cancer Research, 62, 188-199.
55. Yu, C., Krystal, G., Dent, P. & Grant, S. (2002b) Flavopiridol potentiates STI571-induced mitochondrial damage and apoptosis in BCR-ABL-positive human leukemia cells. Clinical Cancer Research, 8, 2976-2984.